Radio and PodcastLive Radio & PodcastsScience & Medicine
147 - Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension
147 - Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension - New FDA Approvals
Related Episodes
Continue listening to more episodes from New FDA Approvals.